Show simple item record

dc.contributor.authorTadesse Awoke
dc.contributor.authorAlemayehu Worku
dc.contributor.authorYigzaw Kebede
dc.contributor.authorAdetayo Kasim
dc.contributor.authorBelay Birlie
dc.contributor.authorRoel Braekers
dc.contributor.authorKhangelani Zuma
dc.contributor.authorZiv Shkedy
dc.date.accessioned2019-10-26T10:57:00Z
dc.date.available2019-10-26T10:57:00Z
dc.date.created2017-11-15 00:03
dc.identifieroai:doaj.org/article:95dcc6a935aa4947b6f28dbac543f1a5
dc.identifier1932-6203
dc.identifier10.1371/journal.pone.0168323
dc.identifierhttps://doaj.org/article/95dcc6a935aa4947b6f28dbac543f1a5
dc.identifier.urihttp://hdl.handle.net/20.500.12424/1732000
dc.description.abstractAntiretroviral therapy has shown to be effective in reducing morbidity and mortality in patients infected with HIV for the past couples of decades. However, there remains a need to better understand the characteristics of long-term treatment outcomes in resource poor settings. The main aim of this study was to determine and compare the long-term response of patients on nevirapine and efavirenz based first line antiretroviral therapy regimen in Ethiopia.Hospital based retrospective cohort study was conducted from January 2009 to December 2013 at University hospital located in Northwest Ethiopia. Human subject research approval for this study was received from University of Gondar Research Ethics Committee and the medical director of the hospital. Cox-proportional hazards model was used to assess the effect of baseline covariates on composite outcome and a semi-parametric mixed effect model was used to investigate CD4 counts response to treatments.A total of 2386 HIV/AIDS naive patients were included in this study. Nearly one-in-four patients experienced the events, of which death, lost to follow up, treatment substitution and discontinuation of Non-Nucleoside Reverse Transcriptase Inhibitors(NNRTI) accounted: 99 (26.8%), 122 (33.0%), 137 (37.0%) and 12 (3.2%), respectively. The hazard of composite outcome on nevirapine compared with efavirenz was 1.02(95%CI: 0.52-1.99) with p-value = 0.96. Similarly, the hazard of composite outcome on tenofovir and stavudine compared with zidovudine were 1.87 (95%CI: 1.52-2.32), p-value < 0.0001 and 1.72(95% CI: 1.22-2.32), p-value = 0.002, respectively. The rate of CD4 increase in response to treatment was high during the first 10 months and stabilized later.This study revealed that treatment responses were comparable whether nevirapine or efavirenz was chosen to initiate antiretroviral therapy for HIV/AIDS patients in Ethiopia. There was significant difference on risk of composite outcome between patients who were initiated with Tenofovir containing ART regimen compared with zidovudine after controlling for NNRTI drug combinations.
dc.languageEN
dc.publisherPublic Library of Science (PLoS)
dc.relation.ispartofhttp://europepmc.org/articles/PMC5173384?pdf=render
dc.relation.ispartofhttps://doaj.org/toc/1932-6203
dc.sourcePLoS ONE, Vol 11, Iss 12, p e0168323 (2016)
dc.subjectMedicine
dc.subjectR
dc.subjectScience
dc.subjectQ
dc.titleModeling Outcomes of First-Line Antiretroviral Therapy and Rate of CD4 Counts Change among a Cohort of HIV/AIDS Patients in Ethiopia: A Retrospective Cohort Study.
dc.typeArticle
ge.collectioncodeOAIDATA
ge.dataimportlabelOAI metadata object
ge.identifier.legacyglobethics:11956810
ge.identifier.permalinkhttps://www.globethics.net/gel/11956810
ge.lastmodificationdate2017-11-15 00:03
ge.lastmodificationuseradmin@pointsoftware.ch (import)
ge.submissions0
ge.oai.exportid149104
ge.oai.repositoryid52
ge.oai.setnameLCC:Medicine
ge.oai.setnameLCC:Science
ge.oai.setspecTENDOk1lZGljaW5l
ge.oai.setspecTENDOlNjaWVuY2U~
ge.oai.streamid2
ge.setnameGlobeEthicsLib
ge.setspecglobeethicslib
ge.linkhttps://doaj.org/article/95dcc6a935aa4947b6f28dbac543f1a5


This item appears in the following Collection(s)

Show simple item record